Bioventix PLC BVXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 3,925.00
- Day Range
- GBX 3,900.00–4,050.00
- 52-Week Range
- GBX 3,402.00–5,100.00
- Bid/Ask
- GBX 3,800.00 / GBX 4,050.00
- Market Cap
- GBX 20.49 Bil
- Volume/Avg
- 4,662 / 3,925
Key Statistics
- Price/Earnings (Normalized)
- 24.98
- Price/Sales
- 15.32
- Dividend Yield (Trailing)
- 4.03%
- Dividend Yield (Forward)
- 4.03%
- Total Yield
- 4.03%
Company Profile
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 16
- Website
- http://www.bioventix.com
Comparables
Valuation
|
Metric
|
BVXP
|
AZN
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.98 | 20.86 | 8.81 |
Price/Book Value | 17.92 | 5.94 | 4.15 |
Price/Sales | 15.32 | 4.79 | 1.68 |
Price/Cash Flow | 22.80 | 22.19 | 10.00 |
Price/Earnings
BVXP
AZN
GSK
Financial Strength
|
Metric
|
BVXP
|
AZN
|
GSK
|
|---|---|---|---|
Quick Ratio | 6.69 | 0.69 | 0.53 |
Current Ratio | 7.04 | 0.89 | 0.82 |
Interest Coverage | — | 5.45 | 8.35 |
Quick Ratio
BVXP
AZN
GSK
Profitability
|
Metric
|
BVXP
|
AZN
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 68.76% | 57.63% | 11.39% |
Return on Equity (Normalized) | 77.21% | 151.23% | 49.79% |
Return on Invested Capital (Normalized) | 76.10% | 84.88% | 22.82% |
Return on Assets
BVXP
AZN
GSK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rwycrddh | Hrzhf | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wgxlrrkjm | Nkmntsf | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xlsrhffx | Wmvbvzy | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cfqyyxbll | Jmwmpkn | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Msgywtqfc | Rwbnh | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vhwsfjzk | Vjp | $28.5 Bil | |||
| Moderna Inc
MRNA
| Qgczprf | Nhdx | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Nrjbjrxpq | Ccykr | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jnvbqjs | Kyslhct | $13.0 Bil | |||
| Incyte Corp
INCY
| Smdmssmr | Hzrhln | $12.9 Bil |
United States